Skip to main content
ADMA
NASDAQ Life Sciences

ADMA Q3 Revenue $141.1M, EPS $0.22; FY26 Revenue Guidance Reiterated, Earnings Outlook Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14
Mkt Cap
$2.347B
52W Low
$7.21
52W High
$20.458
52W Position info
94% above low
Off High info
32% below high
Rel. Volume info
4.5× avg
Market data snapshot near publication time

ADMA sits 94% above its 52-week low of $7.21 on elevated volume (4.5× avg).

Summary

ADMA reported Q3 2026 revenue of $141.1M (up 5%) and GAAP EPS of $0.22 (up 47%), with ASCENIV up 31% offsetting a 35% BIVIGAM decline. Full-year revenue guidance was reiterated at $530M+ while the Adjusted EBITDA floor was raised to $275M+.


Key Events · Earnings and Guidance · ADMA

  • Q3 Revenue $141.1M, EPS $0.22

    Total revenue rose 5% year-over-year to $141.1M and 13% sequentially; GAAP net income was $49.9M and basic EPS $0.22, up 47% from $0.15.

  • ASCENIV Up 31%, BIVIGAM Down 35%

    ASCENIV revenue reached $124.7M (+31% year-over-year, +21% sequentially) while BIVIGAM fell to $15.4M from $23.8M on competitive pricing and channel inventory pressure.

  • FY26 Earnings Outlook Raised

    Revenue guidance reiterated at at least $530M; Adjusted Net Income floor raised to at least $180M and Adjusted EBITDA to at least $275M.

  • SG-001 FDA Feedback Constructive

    FDA feedback on the pre-IND package supports the proposed clinical strategy and assay; ADMA plans to finalize the protocol and prepare an IND submission. Management sizes the opportunity at $300-500M in annual revenue if approved.


Analysis · ADMA · Life Sciences

The quarter itself is strong: ASCENIV revenue rose 31% to $124.7M and gross margin expanded to 71% from 56%, pushing GAAP net income up 37% to $49.9M. The more consequential item is the outlook — management reiterated at least $530M of FY2026 revenue but raised the floor on Adjusted Net Income to at least $180M and Adjusted EBITDA to at least $275M, which implies the margin story is running ahead of prior expectations. Offsetting that, BIVIGAM fell 35% year-over-year to $15.4M on competitive pricing in the standard IG market, so total revenue growth was only 5%. The company also disclosed constructive FDA feedback on its SG-001 pre-IND package, with an IND submission planned next — a $300-500M annual revenue opportunity if approved, but still preclinical. Buybacks remain aggressive: 16.5M shares repurchased year-to-date for $180.3M, with the $200M 2026 target on track.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADMA was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $20.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADMA - Latest Insights

ADMA
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.14
Real-time Price: $13.44 info
Change: +$2.30 (+21%) info
Market Cap: $2.974B info
ADMA
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.98
Real-time Price: $13.44 info
Change: +$3.46 (+35%) info
Market Cap: $2.974B info
ADMA
Aug 05, 2026, 5:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.11
Real-time Price: $13.44 info
Change: +$4.33 (+47%) info
Market Cap: $2.974B info
ADMA
Jul 16, 2026, 10:09 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $8.88
Real-time Price: $13.44 info
Change: +$4.56 (+51%) info
Market Cap: $2.974B info
ADMA
Jul 07, 2026, 6:33 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $9.16
Real-time Price: $13.44 info
Change: +$4.28 (+47%) info
Market Cap: $2.974B info